A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2288-2301

  Mira, Emilia ^a   Carmona Rodríguez, Lorena ^a   Tardáguila, Manuel ^a   Azcoitia, Iñigo ^b   González Martín, Alicia ^a,d   Almonacid, Luis ^a   Casas, Josefina ^c   Fabriás, Gemma ^c   Mañes, Santos ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Inflammation; Lymphoid infiltration; Macrophage polarization; Myeloid infiltration; Statins; Tumor immunity; Vascular normalization

Indexed keywords

DOXORUBICIN; MEVINOLIN; PLACENTAL GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; EFFECTOR CELL; HYPOXIA; INFLAMMATORY INFILTRATE; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE NEU; PERICYTE; POLARIZATION; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR VASCULARIZATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL POLARITY; DOXORUBICIN; FEMALE; LOVASTATIN; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 84891906271     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1376     Document Type: Article

References (58)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-1964.
2. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker R, Korff T, von Deimling A, Unterberg A, Beckhove P and Herold-Mende CC. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived transforming growth factor-beta. Clin Cancer Res. 2011; 17: 4296-4308.
3. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008; 222: 101-116.
4. Hiraoka N, Onozato K, Kosuge T and Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12: 5423-5434.
5. Mantovani A, Allavena P, Sica A and Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436-444.
6. Mantovani A, Sica A, Allavena P, Garlanda C and Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009; 70: 325-330.
7. Sonda N, Chioda M, Zilio S, Simonato F and Bronte V. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol. 2011; 23: 279-285.
8. Bronner LL, Kanter DS and Manson JE. Primary prevention of stroke. N Engl J Med. 1995; 333: 1392-1400.
9. Ehrenstein MR, Jury EC and Mauri C. Statins for atherosclerosis--as good as it gets? N Engl J Med. 2005; 352: 73-75.
10. del Real G, Jiménez-Baranda S, Mira E, Lacalle RA, Lucas P, Gómez-Moutón C, Alegret M, Peña JM, Rodríguez-Zapata M, Alvarez-Mon M, Martínez-A. C and Mañes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med. 2004; 200: 541-547.
11. Jain MK and Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4: 977-987.
12. Greenwood J and Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007; 28: 88-98.
13. Hackam DG, Mamdani M, Li P and Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006; 367: 413-418.
14. Mira E and Mañes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets. 2009; 9: 237-247.
15. Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P and Maltezos E. Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med. 2011; 22: 125-133.
16. Weis M, Heeschen C, Glassford AJ and Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002; 105: 739-745.
17. Coimbra M, Banciu M, Fens MH, de Smet L, Cabaj M, Metselaar JM, Storm G and Schiffelers RM. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J Control Release. 2010; 148: 303-310.
18. Wong WW, Dimitroulakos J, Minden MD and Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002; 16: 508-519.
19. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S and Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006; 66: 8707-8714.
20. Garcia-Ruiz C, Morales A and Fernandez-Checa JC. Statins and protein prenylation in cancer cell biology and therapy. Anticancer Agents Med Chem. 2012; 12: 303-315.
21. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Borresen-Dale AL, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148: 244-258.
22. Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012; 324: 1-12.
23. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A and Jakobisiak M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res. 2000; 6: 2044-2052.
24. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS and Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006; 66: 7370-7377.
25. Jakobisiak M and Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev. 2010; 30: 102-135.
26. Chen Y, Zhang S, Peng G, Yu J, Liu T, Meng R, Li Z, Zhao Y and Wu G. Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: pleiotropic and dose-dependent effect on tumor vascular stabilization. Int J Oncol. 2013; 42: 1325-1336.
27. Boucher K, Siegel CS, Sharma P, Hauschka PV and Solomon KR. HMG-CoA reductase inhibitors induce apoptosis in pericytes. Microvasc Res. 2006; 71: 91-102.
28. Lustgarten J, Dominguez AL and Cuadros C. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol. 2004; 34: 752-761.
29. González-Martín A, Gómez L, Lustgarten J, Mira E and Mañes S. Maximal T Cell-Mediated Antitumor Responses Rely upon CCR5 Expression in Both CD4+ and CD8+ T Cells. Cancer Res. 2011; 71: 5455-5466.
30. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Akerud P, De Mol M, Salomaki H, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011; 19: 31-44.
31. Mira E, León B, Barber DF, Jiménez-Baranda S, Goya I, Almonacid L, Marquez G, Zaballos A, Martínez-A. C, Stein JV, Ardavin C and Mañes S. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol. 2008; 181: 3524-3534.
32. Manzur M, Hamzah J and Ganss R. Modulation of G protein signaling normalizes tumor vessels. Cancer Res. 2009; 69: 396-399.
33. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragones J, Debackere K, Luttun A, Wyns S, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009; 136: 839-851.
34. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007; 131: 463-475.
35. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
36. McKay A, Leung BP, McInnes IB, Thomson NC and Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004; 172: 2903-2908.
37. Zeki AA, Franzi L, Last J and Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009; 180: 731-740.
38. Silveira AA, Dominical VM, Lazarini M, Costa FF and Conran N. Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity. Inflamm Res. 2013; 62: 127-132.
39. Feig JE, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, Shamir R, Torra IP, Fernandez-Hernando C, Fisher EA and Garabedian MJ. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One. 2011; 6: e28534.
40. Maruyama T, Kono K, Izawa S, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M and Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus. 2010; 23: 422-429.
41. Sica A and Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122: 787-795.
42. Fujita E, Shimizu A, Masuda Y, Kuwahara N, Arai T, Nagasaka S, Aki K, Mii A, Natori Y, Iino Y, Katayama Y and Fukuda Y. Statin attenuates experimental anti-glomerular basement membrane glomerulonephritis together with the augmentation of alternatively activated macrophages. Am J Pathol. 2010; 177: 1143-1154.
43. van der Meij E, Koning GG, Vriens PW, Peeters MF, Meijer CA, Kortekaas KE, Dalman RL, van Bockel JH, Hanemaaijer R, Kooistra T, Kleemann R and Lindeman JH. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One. 2013; 8: e53882.
44. Hilfenhaus G, Gohrig A, Pape UF, Neumann T, Jann H, Zdunek D, Hess G, Stassen JM, Wiedenmann B, Detjen K, Pavel M and Fischer C. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. Endocr Relat Cancer. 2013; 20: 305-319.
45. Lewis CE and Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66: 605-612.
46. DeNardo DG, Andreu P and Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010; 29: 309-316.
47. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN and Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013; 109: 318-324.
48. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT and Olsen JH. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005; 114: 643-647.
49. Murtola TJ, Tammela TL, Maattanen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH and Auvinen A. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer. 2010; 127: 1650-1659.
50. Ferris JS, McCoy L, Neugut AI, Wrensch M and Lai R. HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012; 131: E1031-1037.
51. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, Di Carlo E, Musiani P, Forni G, Menard S and Lollini PL. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer. 2000; 87: 186-194.
52. Murphy JE, Morales RE, Scott J and Kupper TS. IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol. 2003; 170: 5697-5703.
53. Gautier L, Cope L, Bolstad BM and Irizarry RA. Affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20: 307-315.
54. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3: Article3.
55. Benjamini Y and Hochberg Y. Controling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995; 57: 289-300.
56. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, Carazo JM and Pascual-Montano A. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 2009; 37: W317-322.
57. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM and Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007; 8: R3.
58. Tardáguila M, Mira E, Garcia-Cabezas MA, Feijoo AM, Quintela-Fandino M, Azcoitia I, Lira SA and Mañes S. CX3CL1 Promotes Breast Cancer via Transactivation of the EGF Pathway. Cancer Res. 2013; 73: 4461-4473.